The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials

To assess the long-term cost-effectiveness of novel glucagon-like peptide-1 (GLP-1) analog oral semaglutide versus sodium-glucose cotransporter-2 inhibitor empagliflozin, dipeptidyl peptidase-4 inhibitor sitagliptin and injectable GLP-1 analog liraglutide in the Netherlands, based on the results of the PIONEER clinical trials.

Source: Diabetes Research and Clinical Practice - March 17, 2021 Category: Endocrinology Authors: Samuel J.P. Malkin, Barnaby Hunt, Eline L. Huisman, Tobias S. Grand, Barrie Chubb Source Type: research